216 related articles for article (PubMed ID: 21239999)
1. Combinations of 3-hydroxyphthalic anhydride-modified ovalbumin with antiretroviral drug-based microbicide candidates display synergistic and complementary effects against HIV-1 infection.
Li L; Tan S; Lu H; Lu L; Yang J; Jin H; Liu S; Jiang S
J Acquir Immune Defic Syndr; 2011 Apr; 56(5):384-92. PubMed ID: 21239999
[TBL] [Abstract][Full Text] [Related]
2. 3-hydroxyphthalic anhydride-modified chicken ovalbumin exhibits potent and broad anti-HIV-1 activity: a potential microbicide for preventing sexual transmission of HIV-1.
Li L; He L; Tan S; Guo X; Lu H; Qi Z; Pan C; An X; Jiang S; Liu S
Antimicrob Agents Chemother; 2010 May; 54(5):1700-11. PubMed ID: 20194691
[TBL] [Abstract][Full Text] [Related]
3. Maleic anhydride-modified chicken ovalbumin as an effective and inexpensive anti-HIV microbicide candidate for prevention of HIV sexual transmission.
Li L; Qiao P; Yang J; Lu L; Tan S; Lu H; Zhang X; Chen X; Wu S; Jiang S; Liu S
Retrovirology; 2010 Apr; 7():37. PubMed ID: 20420669
[TBL] [Abstract][Full Text] [Related]
4. 3-Hydroxyphthalic anhydride-modified human serum albumin as a microbicide candidate inhibits HIV infection by blocking viral entry.
Li L; Qiu J; Lu L; An S; Qiao P; Jiang S; Liu S
J Antimicrob Chemother; 2013 Mar; 68(3):573-6. PubMed ID: 23221626
[TBL] [Abstract][Full Text] [Related]
5. [Antiviral activity of 3-hydroxyphthalic anhydride-modified ovalbumin against herpes simplex virus 2 in vitro].
He LL; Duan JM; Qiu JY; Yu F; Liu SW; Li L
Nan Fang Yi Ke Da Xue Xue Bao; 2011 Jun; 31(7):1175-8. PubMed ID: 21764688
[TBL] [Abstract][Full Text] [Related]
6. 3-hydroxyphthalic anhydride-modified human serum albumin as a microbicide candidate against HIV type 1 entry by targeting both viral envelope glycoprotein gp120 and cellular receptor CD4.
Li M; Duan J; Qiu J; Yu F; Che X; Jiang S; Li L
AIDS Res Hum Retroviruses; 2013 Nov; 29(11):1455-64. PubMed ID: 23711095
[TBL] [Abstract][Full Text] [Related]
7. Maraviroc and reverse transcriptase inhibitors combinations as potential preexposure prophylaxis candidates.
Herrera C; Armanasco N; García-Pérez J; Ziprin P; Olejniczak N; Alcamí J; Nuttall J; Shattock RJ
AIDS; 2016 Apr; 30(7):1015-25. PubMed ID: 26854808
[TBL] [Abstract][Full Text] [Related]
8. Superior Efficacy of a Human Immunodeficiency Virus Vaccine Combined with Antiretroviral Prevention in Simian-Human Immunodeficiency Virus-Challenged Nonhuman Primates.
Le Grand R; Dereuddre-Bosquet N; Dispinseri S; Gosse L; Desjardins D; Shen X; Tolazzi M; Ochsenbauer C; Saidi H; Tomaras G; Prague M; Barnett SW; Thiebaut R; Cope A; Scarlatti G; Shattock RJ
J Virol; 2016 Jun; 90(11):5315-5328. PubMed ID: 27009957
[TBL] [Abstract][Full Text] [Related]
9. CADA, a novel CD4-targeted HIV inhibitor, is synergistic with various anti-HIV drugs in vitro.
Vermeire K; Princen K; Hatse S; De Clercq E; Dey K; Bell TW; Schols D
AIDS; 2004 Nov; 18(16):2115-25. PubMed ID: 15577644
[TBL] [Abstract][Full Text] [Related]
10. Tropism-independent protection of macaques against vaginal transmission of three SHIVs by the HIV-1 fusion inhibitor T-1249.
Veazey RS; Ketas TA; Klasse PJ; Davison DK; Singletary M; Green LC; Greenberg ML; Moore JP
Proc Natl Acad Sci U S A; 2008 Jul; 105(30):10531-6. PubMed ID: 18647836
[TBL] [Abstract][Full Text] [Related]
11. Combination of candidate microbicides cellulose acetate 1,2-benzenedicarboxylate and UC781 has synergistic and complementary effects against human immunodeficiency virus type 1 infection.
Liu S; Lu H; Neurath AR; Jiang S
Antimicrob Agents Chemother; 2005 May; 49(5):1830-6. PubMed ID: 15855503
[TBL] [Abstract][Full Text] [Related]
12. Virucidal activity of the dendrimer microbicide SPL7013 against HIV-1.
Telwatte S; Moore K; Johnson A; Tyssen D; Sterjovski J; Aldunate M; Gorry PR; Ramsland PA; Lewis GR; Paull JR; Sonza S; Tachedjian G
Antiviral Res; 2011 Jun; 90(3):195-9. PubMed ID: 21459115
[TBL] [Abstract][Full Text] [Related]
13. A novel preventive strategy against HIV-1 infection: combinatorial use of inhibitors targeting the nucleocapsid and fusion proteins.
Yang Y; Zhu J; Hassink M; Jenkins LMM; Wan Y; Appella DH; Xu J; Appella E; Zhang X
Emerg Microbes Infect; 2017 Jun; 6(6):e40. PubMed ID: 28588284
[TBL] [Abstract][Full Text] [Related]
14. The New NNRTI ACC007 Combined with Lamivudine and Tenofovir Disoproxil Fumarate Show Synergy Anti-HIV Activity In Vitro.
Huang XS; Luo RH; Hu XL; Chen H; Xiang SY; Tang CR; Zhang CT; Shen XN; Zheng YT
Curr HIV Res; 2020; 18(5):332-341. PubMed ID: 32562524
[TBL] [Abstract][Full Text] [Related]
15. Chemically Modified Human Serum Albumin Potently Blocks Entry of Ebola Pseudoviruses and Viruslike Particles.
Li H; Yu F; Xia S; Yu Y; Wang Q; Lv M; Wang Y; Jiang S; Lu L
Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167539
[TBL] [Abstract][Full Text] [Related]
16. Synergistic effect resulting from combinations of a bifunctional HIV-1 antagonist with antiretroviral drugs.
Xu W; Wang Q; Yu F; Lu L; Jiang S
J Acquir Immune Defic Syndr; 2014 Sep; 67(1):1-6. PubMed ID: 24977378
[TBL] [Abstract][Full Text] [Related]
17. CADA, a potential anti-HIV microbicide that specifically targets the cellular CD4 receptor.
Vermeire K; Brouwers J; Van Herrewege Y; Le Grand R; Vanham G; Augustijns P; Bell TW; Schols D
Curr HIV Res; 2008 May; 6(3):246-56. PubMed ID: 18473788
[TBL] [Abstract][Full Text] [Related]
18. Combinations of the first and next generations of human immunodeficiency virus (HIV) fusion inhibitors exhibit a highly potent synergistic effect against enfuvirtide- sensitive and -resistant HIV type 1 strains.
Pan C; Cai L; Lu H; Qi Z; Jiang S
J Virol; 2009 Aug; 83(16):7862-72. PubMed ID: 19493996
[TBL] [Abstract][Full Text] [Related]
19. Characterization of HIV-1 entry inhibitors with broad activity against R5 and X4 viral strains.
Sironi F; Malnati M; Mongelli N; Cozzi P; Guzzo C; Ghezzi S; Martínez-Romero C; García-Sastre A; Lusso P; Jabes D; Biswas P
J Transl Med; 2015 Apr; 13():107. PubMed ID: 25888743
[TBL] [Abstract][Full Text] [Related]
20. Nanoparticle-Based ARV Drug Combinations for Synergistic Inhibition of Cell-Free and Cell-Cell HIV Transmission.
Jiang Y; Cao S; Bright DK; Bever AM; Blakney AK; Suydam IT; Woodrow KA
Mol Pharm; 2015 Dec; 12(12):4363-74. PubMed ID: 26529558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
